AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01919814 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Appethyl™
Description: Four hours after breakfast participants will be given a small amount of liquid to drink that will contain Appethyl™. They will not know which they are getting and it will be decided randomly, like flipping a coin. Participants will be presented with a pizza in a quantity more than they could reasonably be expected to eat 5 hours after the start of their lunch meal and be asked to eat to their satisfaction over 30 minutes. Participants are not expected to eat all of the pizza.
Study NCT01919814 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Appethyl™
Description: Four hours after breakfast participants will be given a small amount of liquid to drink that will contain Appethyl™. They will not know which they are getting and it will be decided randomly, like flipping a coin. Participants will be presented with a pizza in a quantity more than they could reasonably be expected to eat 5 hours after the start of their lunch meal and be asked to eat to their satisfaction over 30 minutes. Participants are not expected to eat all of the pizza.
Study NCT01919814 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Four hours after breakfast, participants will be given a small amount of liquid to drink that will contain a placebo (inactive liquid). Participants will not know which they are getting and it will be decided randomly, like flipping a coin. Participants will be presented with a pizza in a quantity more than they could reasonably be expected to eat 5 hours after the start of their lunch meal and be asked to eat to their satisfaction over 30 minutes. They are not expected to eat all of the pizza.
Study NCT01919814 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Four hours after breakfast, participants will be given a small amount of liquid to drink that will contain a placebo (inactive liquid). Participants will not know which they are getting and it will be decided randomly, like flipping a coin. Participants will be presented with a pizza in a quantity more than they could reasonably be expected to eat 5 hours after the start of their lunch meal and be asked to eat to their satisfaction over 30 minutes. They are not expected to eat all of the pizza.
Study NCT03890718 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Photorefractive keratectomy in mile keratoconus
Description: Topo-guided photorefractive keratectomy will be performed using an excimer laser (Allegretto Wave Topolyzer, Alcon, Inc.) with a 6 mm optical area and a transition area of 2 mm in all eyes. At that point, the partial topography-guided photorefractive keratectomy laser treatment will be finished. The arrangement will be to treat 70% of the cylindrical and spherical part to not surpass 50μm of stromal expulsion. The estimation of 50μm as the most extreme removal depth recommended by Kanellopoulos in Athens protocol will be chosen
Study NCT00275262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate depot (LAD) 11.25 mg 3 Month
Description: LAD intramuscular injection 11.25 mg, 3 month duration. To stimulate immune response, a subcutaneous key limpet hemocyanin (KLH) vaccination injection (1 mg) was administered at Month 6.
Study NCT00275262 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matched placebo
Description: Matched placebo intramuscular injection, 3 month duration. To stimulate immune response, a subcutaneous key limpet hemocyanin (KLH) vaccination injection (1 mg) was administered at Month 6.
Study NCT00597298 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Threshold
Description: Inspiratory muscle training program using a variable pressure device. An inspiratory muscle training device comprises a chamber having an opening for the passage of air to be inhaled and exhaled, and an inlet permitting air to be inhaled to enter the chamber and to pass to the opening. A one-way exhaust valve permits exhaled air entering through the opening to escape from the chamber, and another valve is provided to resist the entry of air to be inhaled into the chamber, the latter valve serving to vary the degree of resistance in dependence upon the volume of air that has passed through the inlet.
Study NCT00597298 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham threshold
Description: non-training physical activity
Study NCT02839642 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivastigmine
Study NCT02839642 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01422226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: Experimental: 400 mcg taken sublingually 2 hours prior to IUD insertion
Study NCT01422226 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pill identical to study drug in appearance, taste, smell. Taken sublingually 2 hours prior to IUD insertion
Study NCT01817153 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydrocortison hemisuccinate
Study NCT01817153 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo followed by hydrocortisone hemisuccinate
Study NCT03545958 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-intensity Interval Training (HIT)
Description: Following the mind-motor training component, participants in the experimental group will then continue in the 45-minute HIT intervention, which will be composed by a 10-minute warm-up, a 25-minute core activity, and a 10-minute cool down. The 25-minute core activity will be carried out based on a 4 x 4 minutes aerobic interval training model. The intensity in each cycle will be prescribed at an individual level, and training heart rates will be determined via a sub-maximal excise testing at baseline and monitored during exercise using a wrist-based heart rate monitor (Suunto). In order to ensure progression in aerobic training over the 6-month intervention, training heart rates will be recalculated at the intervention midpoint (i.e., 3 months), where a new sub-maximal exercise test will be performed. Participants will exercise 60 minutes/day, 3 days/week for 6 months.
Study NCT02707731 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hydrokinesiotherapy
Description: physical therapy technique used in a plastic bucket approved by ANVISA , with water temperature monitored at 37 ° C, water level up to the shoulders and by the physical properties of water, was allowed to mobilize the newborn facilitating the feeling of relaxation and standard suitable movement.
Study NCT02340767 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectra Device
Description: Spectra Caries detection device is used for study data collection recording the results of the dental examination and recording results of dental treatment.
Study NCT02340767 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DIAGNOdent
Description: DIAGNOdent Caries detection device is used for study data collection recording the results of the dental examination and recording results of dental treatment.
Study NCT01440374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eltrombopag
Description: 100 mg daily (50 mg for subjects of East Asian heritage), intra-subject dose escalations to a maximum dose of 300 mg (150 mg for subjects of East Asian heritage)
Study NCT01440374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: 100 mg matching placebo daily (50 mg for subjects of East Asian heritage), intra-subject dose escalations to a maximum dose of 300 mg matching placebo (150 mg for subjects of East Asian heritage)
Study NCT00924261 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hip Stretch
Description: Hip flexor stretch daily for 3 min x 10 weeks
Study NCT00924261 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shoulder Stretch
Description: Shoulder Adduction stretch - 3 minutes, daily, for 10 weeks
Study NCT01966380 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Leia
Study NCT01966380 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Leia
Study NCT02070133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Simvastatin 40 mg once a day during 12 weeks
Study NCT02070133 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once a day during 12 weeks
Study NCT04153123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine
Study NCT00734383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol cardioprotection : Ten minutes prior to initiation of CPB, we will stop delivery of isoflurane, inject 1 mg/kg iv and then continuously infuse propofol at 120µg/kg/min IV until 15 min after release of the aortic cross clamp (reperfusion).
Study NCT00734383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Volatile Anesthetic preconditioning : Anesthesia will be maintained using an inspired concentration of isoflurane between 0.5-2% before, during, and after CPB, without administration of propofol. For ten minutes prior to the initiation of CPB we will deliver Isoflurane 2.5% end tidal then resume maintenance anesthesia as described.
Study NCT00925431 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Modification
Description: 16 hours of motivational, lifestyle management session, 8 hours nutritional education.
Study NCT00925431 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive education
Description: 16 hours general fibromyalgia education, 8 hours of nutritional education
Study NCT01592500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOD-4023
Description: Once weekly subcutaneous injection
Study NCT01592500 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Somatropin
Description: Once daily subcutaneous injection of Genotropin
Study NCT03251781 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation
Description: Pulmonary rehabilitation program (PRP) was conducted according to the guidelines of the American Thoracic Society/European Respiratory Society (Nici et al., 2006; Spruit et al., 2013). Physical training was conducted over 24 sessions supervised, three times a week. The program included aerobic training in treadmill (with 30 min load determined by the dyspnea sensation - 4 to 6 on the modified Borg scale) and localized training for upper limbs with free weights or elastic bands (movements performed based on the proprioceptive neuromuscular facilitation diagonals, performed in two series, lasting two minutes each) and lower limbs (quadriceps and triceps sural) with free weights and/or in the bodybuilding station.
Study NCT00690443 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: atorvastatin 20 mg tablets, daily dosing, for 8 weeks.
Study NCT00690443 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AEGR-733
Description: 2.5 mg AEGR-733 capsules, daily dosing, 4 weeks followed by 5 mg AEGR-733 capsules, daily dosing, 4 weeks
Study NCT04171453 — intervention group
Intervention type: DRUG
Intervention: Lyrica CR (Pregabalin)
Description: Lyrica CR 82.5mg, 165mg, or 330mg OD
Study NCT02726685 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: respiratory training.
Description: breathing exercise.
Study NCT02726685 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham training.
Description: range of motion (ROM) exercise, stretching exercise or positioning exercise.
Study NCT01493011 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: chemotherapy & WBH
Description: standard first-line chemotherapy combined with whole-body hyperthemia to treat stage Ⅲb/Ⅳ NSCLC
Study NCT01451125 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous cultured dermal and epidermal cells
Description: A piece of occipital scalp is taken from the subject. The epidermal and dermal cells from this tissue are expanded in culture. The cells are then harvested and, for certain types of product, combined. These cells are then injected into the balding area of the scalp of the original subject.
Study NCT04017039 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Targeted Sleep Intervention
Study NCT00320541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 1500 mg/m2, IV day 1 and day 15 every 28 days until complete response, disease progression or unacceptable toxicity
Study NCT00320541 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: 90 mg/m2, IV, day 1, day 8 and day 15 every 28 days until complete response, disease progression or unacceptable toxicity
Study NCT03545958 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate-intensity Continuous Training (MCT)
Description: After the mind-motor training component, participants in the comparison/control group will then continue in the 45-min MCT intervention, which will be composed by a 10-minute warm-up a 25-minute moderate-intensity continuous aerobic exercise training, and a 10-minute cool down. The exercise intensity will be prescribed at an individual level, and training heart rates will be determined via a sub-maximal excise testing at baseline and monitored during exercise using a wrist-based heart rate monitor (Suunto). In order to ensure progression in aerobic training over the 6-month intervention, training heart rates will be recalculated at the intervention midpoint (i.e., 3 months), where a new sub-maximal exercise test will be performed. Participants will exercise 60 minutes/day, 3 days/week for 6 months.
Study NCT00320541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 90 mg/m2, IV, day 1, day 8 and day 15 every 28 days until complete response, disease progression or unacceptable toxicity
Study NCT00320541 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab
Description: 10 mg/kg, IV, day 1 and day 15 every 28 days until complete response, disease progression or unacceptable toxicity
Study NCT00320541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 10 mg/kg, IV, day 1 and day 15 every 28 days until complete response, disease progression or unacceptable toxicity
Study NCT02401360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: China Crest® Pro-health 7 Complete Toothpaste
Description: Crest® pro-health manual toothbrush Crest® pro-health gum protection rinse
Study NCT02401360 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: China Crest® Cavity Protection Toothpaste
Description: Crest® meliliangje manual toothbrush
Study NCT03294746 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Clinical evaluations
Description: At study entry , 6 weeks and 6 months, enrolled patients will undergo pulmonary physiology tests, assessment of respiratory symptoms, respiratory examination, pulse oximetry, blood draws, respiratory and quality of life assessment. Data from bronchoscopy assessments will be collected, if this has been performed as part of routine care.
Study NCT03294746 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Thoracic CT
Description: At study entry, patients will undergo thoracic CT before treatment adaptation, unless a study-quality scan\* has already been performed . Thoracic CT will be repeated at 6 weeks. All images will be centrally reviewed for radiology scoring.
Study NCT03029312 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Galileo M
Description: Motorized board producing side-to-side alternating vertical sinusoidal (rotational) vibrations around a fulcrum in the mid-section of the plate. The vibration frequency can be selected by the user who stands on the board with both feet, wearing shoes. The peak-to-peak displacement to which the feet are exposed increases with the distance of the feet from the centre line of the vibrating board. Three positions marked 1, 2 and 3 are indicated on the vibrating board, corresponding to peak-to-peak displacements of 2, 4, and 6mm. The peak acceleration exerted by vibration exercise increases with higher frequencies and higher amplitudes.
Study NCT02263937 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral Nucleus Basalis Meynert DBS
Description: Low frequency stimulation applied using standard Deep brain stimualtion hardware.
Study NCT02263937 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Nucleus Basalis Meynert DBS
Description: DBS system switched off.
Study NCT00901277 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: web intervention
Description: A multi-behavioral, comprehensive approach is proposed addressing up to 13 health behaviors focused on improving subject management of CVD and related health behaviors. This is a web-based intervention.
Study NCT00901277 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nurse intervention
Description: A multi-behavioral, comprehensive approach is proposed addressing up to 13 health behaviors focused on improving subject management of CVD and related health behaviors given by the nurse via phone.
Study NCT03553368 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HF-NIV-MR
Description: MRI data will be acquired with the use of HF-NIV.
Study NCT03553368 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HF-NIV-PET
Description: PET data will be acquired with the use of HF-NIV.
Study NCT03553368 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MR
Description: MRI data will be acquired without the use of any device as a reference.
Study NCT03553368 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/CT breath hold
Description: PET/CT data will be acquired in inspiratory breath hold without the use of HF-NIV.
Study NCT03553368 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CPAP-MR
Description: MRI data will be acquired with the use of CPAP.
Study NCT02522351 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cereal extract concentration 1
Description: Cereal extract will be given to see the effect on penetration and aspiration in patients with dysphagia problem
Study NCT03208946 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-CML diet
Description: Participants will be randomly assigned to either a high-CML or to a low-CML diet for 5 days, and they will receive the 5 corresponding meals (breakfast, lunch, snacks and dinner) during the 5 days of the intervention. These preparations will be elaborated by a catering company with indications and supervision by the research group. The intervention will be based on an isocaloric diet with a distribution of 55 to 63% carbohydrates, 12 to 15% protein, 25 to 30% lipids and less than 10% saturated fat and it macro and micronutrients will be similar in both diets. The only difference will be the CML content.
Study NCT03208946 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Low-CML diet
Description: Participants will be randomly assigned to either a high-CML or to a low-CML diet for 5 days, and they will receive the 5 corresponding meals (breakfast, lunch, snacks and dinner) during the 5 days of the intervention. These preparations will be elaborated by a catering company with indications and supervision by the research group. The intervention will be based on an isocaloric diet with a distribution of 55 to 63% carbohydrates, 12 to 15% protein, 25 to 30% lipids and less than 10% saturated fat and it macro and micronutrients will be similar in both diets. The only difference will be the CML content.
Study NCT02059278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-2345
Description: T-2345 Ophthalmic Solution
Study NCT02059278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xalatan
Description: Xalatan (latanoprost 0.005% ophthalmic solution)
Study NCT01907854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Starting dose of 0.6 mg/day, with weekly dose escalations of 0.6 mg/day until the maintenance dose of 1.8 mg/day is reached. Administered subcutaneously (s.c., under the skin) once daily + metformin tablets (at least 1000 mg/day)
Study NCT01907854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin
Description: 100 mg/day sitagliptin tablets once-daily + metformin (at least 1000 mg/day)
Study NCT01907854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Sitagliptin placebo tablets once-daily
Study NCT02930863 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pulse oximetry software
Description: This pulse oximetry software will utilize automated verbal prompts that direct the patients to breathe when their pulse oximetry reading falls at or below 93%.
Study NCT02930863 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief post-PACU stay survey.
Description: Complete a brief post-PACU stay survey focused around their satisfaction and experience during their time in the PACU.
Study NCT02930863 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief post-PACU stay survey.
Description: Complete a brief post-PACU stay survey focused around their satisfaction and experience during their time in the PACU.
Study NCT02522351 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cereal extract concentration 1
Description: Cereal extract will be given to see the effect on penetration and aspiration in patients with dysphagia problem
Study NCT02522351 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cereal extract concentration 2
Description: Cereal extract will be given to see the effect on penetration and aspiration in patients with dysphagia problem
Study NCT02522351 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cereal extract concentration 2
Description: Cereal extract will be given to see the effect on penetration and aspiration in patients with dysphagia problem